Too many directions in Ebola research could hinder search for cure

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

When it comes to treatments for Ebola, there has been a nearly four-decade-long drought. Nothing in the medical arsenal attacks the virus directly. For the most part, patients receive only supportive care, offered at a minimum level if too few health-care workers struggle to keep too many patients alive.

The current extraordinary outbreak in West Africa provides, really for the first time, a chance to change that. This, the largest outbreak on record, presents an opportunity to test some therapies in the hopes that those caring for future Ebola patients will never again despair at the fact that the best they can offer is a bed, fluids, nutrition and human kindness.

But that drought could give way to a free-for-all if the world is not careful, some experts worry. Driven by the enormity of this epidemic and the prospect of months more to come, there is a sharp desire in some quarters to try almost anything that might help.

It is not a position all endorse. “I think we have to go forward based on scientific evidence, not on belief,” says Martin Friede, the World Health Organization’s team leader for work on experimental Ebola drugs. “There are situations where doing nothing is actually better than doing something that is not justified.”

Read full original article: Ebola Free-For-All Could Trigger Bad Science and Wasted Efforts

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend